PURPOSE: Overexpression of transketolase-like gene 1 (TKTL1) on RNA and protein level has been linked to tumour progression, metastasis and unfavourable patient outcome in many solid tumours. Chronic myeloid leukaemia (CML) cells show metabolic characteristics resembling deviations observed in TKTL1 overexpressing solid tumour cells. We therefore sought to evaluate TKTL1 gene expression in different phases of CML. METHODS: A total of 120 peripheral blood samples from 69 patients in various phases of CML and 21 healthy individuals were investigated. TKTL1 expression levels were determined by real-time quantitative polymerase chain reaction using LightCycler technology and normalised against beta-glucuronidase expression. RESULTS: A significantly lower TKTL1 expression was found in chronic phase (CP) CML patients compared to healthy controls. Lowest expression levels were observed in patients during blast crisis (BC). Baseline TKTL1 expression in CP patients did not have value in prognostication of subsequent favourable or dismal outcome. Further, more mature granulocytes showed significantly higher TKTL1 expression compared to immature CD34+ and CD34-/CD33+ cells both in healthy controls and in CML patients. CONCLUSION: TKTL1 expression levels appear to decline in the course of CML with lowest levels during BC. A potential reason is a shift of TKTL1-high-expressing mature granulocytes towards TKTL1-low-expressing immature cells and blasts.
PURPOSE: Overexpression of transketolase-like gene 1 (TKTL1) on RNA and protein level has been linked to tumour progression, metastasis and unfavourable patient outcome in many solid tumours. Chronic myeloid leukaemia (CML) cells show metabolic characteristics resembling deviations observed in TKTL1 overexpressing solid tumour cells. We therefore sought to evaluate TKTL1 gene expression in different phases of CML. METHODS: A total of 120 peripheral blood samples from 69 patients in various phases of CML and 21 healthy individuals were investigated. TKTL1 expression levels were determined by real-time quantitative polymerase chain reaction using LightCycler technology and normalised against beta-glucuronidase expression. RESULTS: A significantly lower TKTL1 expression was found in chronic phase (CP) CMLpatients compared to healthy controls. Lowest expression levels were observed in patients during blast crisis (BC). Baseline TKTL1 expression in CPpatients did not have value in prognostication of subsequent favourable or dismal outcome. Further, more mature granulocytes showed significantly higher TKTL1 expression compared to immature CD34+ and CD34-/CD33+ cells both in healthy controls and in CMLpatients. CONCLUSION:TKTL1 expression levels appear to decline in the course of CML with lowest levels during BC. A potential reason is a shift of TKTL1-high-expressing mature granulocytes towards TKTL1-low-expressing immature cells and blasts.
Authors: M C Müller; P Erben; G Saglio; E Gottardi; C G Nyvold; T Schenk; T Ernst; S Lauber; J Kruth; R Hehlmann; A Hochhaus Journal: Leukemia Date: 2007-10-18 Impact factor: 11.528
Authors: Martha Földi; Elmar Stickeler; Lidija Bau; Oliver Kretz; Dirk Watermann; Gerald Gitsch; Gian Kayser; Axel Zur Hausen; Johannes F Coy Journal: Oncol Rep Date: 2007-04 Impact factor: 3.906
Authors: Wiltrud Haaß; Michael Stehle; Stefanie Nittka; Michelle Giehl; Petra Schrotz-King; Alice Fabarius; Wolf-Karsten Hofmann; Wolfgang Seifarth Journal: PLoS One Date: 2012-08-03 Impact factor: 3.240
Authors: S Langbein; M Zerilli; A Zur Hausen; W Staiger; K Rensch-Boschert; N Lukan; J Popa; M P Ternullo; A Steidler; C Weiss; R Grobholz; F Willeke; P Alken; G Stassi; P Schubert; J F Coy Journal: Br J Cancer Date: 2006-02-27 Impact factor: 7.640